GENB Stock Forecast: Generate Biomedicines, Inc. Price Predictions for 2026-2027
The 6 Wall Street analysts covering Generate Biomedicines, Inc. hold a median 12-month price target of $25 — +74.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 1 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
GENB stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Generate Biomedicines, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (51): Analysts have, on balance, been raising their forecasts.
Quality (3): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
The rank is the raw material. Whether the rules would actually own Generate Biomedicines, Inc. — and when they’d sell — is the membership.
GENB stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on GENB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +74.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 May 2026 | Morgan Stanley | Maintains | Overweight | $20 → $22 |
| 8 May 2026 | HC Wainwright & Co. | Maintains | Buy | $16 → $25 |
| 13 Apr 2026 | HC Wainwright & Co. | Initiates | Buy | — |
| 24 Mar 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
| 24 Mar 2026 | Goldman Sachs | Initiates | Buy | — |
| 24 Mar 2026 | Guggenheim | Initiates | Buy | — |
| 24 Mar 2026 | Morgan Stanley | Initiates | Overweight | — |
| 24 Mar 2026 | Piper Sandler | Initiates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
GENB analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Generate Biomedicines, Inc. (GENB) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −6.4×
- Price / sales
- 59.2×
- Price / book
- 3.5×
- EV / EBITDA
- −5.6×
Cheaper than 91% of US stocks
Cheaper than 5% of US stocks
Cheaper than 30% of US stocks
Cheaper than 80% of US stocks
- Revenue growth (YoY)
- −18.1%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −887.5%
- Net margin
- 0.0%
Higher than 12% of US stocks
Higher than 6% of US stocks
Higher than 30% of US stocks
- Return on equity
- 40.0%
- Return on assets
- −75.6%
- Dividend yield
- —
Higher than 91% of US stocks
Higher than 4% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
GENB vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GENB appears on the weeks it earns a place.
Frequently asked questions about GENB stock
What is the GENB stock price forecast for 2026-2027?
The 6 Wall Street analysts covering Generate Biomedicines, Inc. have a median 12-month price target of $25, with estimates ranging from $22 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is GENB stock a buy right now?
Of the 6 analysts covering Generate Biomedicines, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Generate Biomedicines, Inc. 1 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank GENB?
As at 1 Aug 2026, Generate Biomedicines, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (51 of 100).
Will GENB stock go up?
No one can know that. What the data says: the median 12-month target from 6 analysts implies +74.3% from the last close, and Ticker Nerd's factor model ranks Generate Biomedicines, Inc. 1 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the GENB stock forecast for 2030?
No analyst covering Generate Biomedicines, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GENB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $30 over the next 12 months.
What does Generate Biomedicines, Inc. do?
Generate Biomedicines, Inc. is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development.
About Generate Biomedicines, Inc.
Generate Biomedicines, Inc. is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. Its primary purpose is to program biology to generate optimal therapeutics for significant impact on human health, leveraging the Generate Platform, a therapeutic area and protein modality agnostic system. This platform integrates computational innovation with scalable biohardware in a fully-integrated design–build–test–learn loop to create proprietary data and differentiated molecular solutions. It engineers proteins against therapeutic targets, either from existing references or through de novo design, addressing challenges beyond traditional technologies. The platform has advanced computationally engineered proteins into human clinical testing, including GB-0895, an investigational long-acting anti-TSLP monoclonal antibody enrolling patients in pivotal Phase 3 trials for severe asthma. Generate Biomedicines, Inc. also advances oncology product candidates toward clinical stages. Operating at the intersection of machine learning, biological engineering, and medicine, the company focuses on protein-based modalities across multiple disease areas to transform drug discovery into systematic drug generation. Founded in 2018 and headquartered in Somerville, Massachusetts, it plays a key role in advancing AI-driven biotherapeutics in the healthcare sector.
CEO Mr. Michael T. Nally M.B.A. · 312 employees · United States · https://generatebiomedicines.com